Primary cutaneous ALCL is a CD30+ T-cell lymphoproliferative disorder having a relatively favorable prognosis, with a 10-year survival rate of 90% in the absence of advanced stage disease. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.